Cited by 321Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Open access

Ferris, Robert L., Jaffee, Elizabeth M., Ferrone, Soldano·2010·Journal of Clinical Oncology

DOI 10.1200/jco.2009.27.6360PMC PMC2954137

Open this paper in CoChat — free account

Abstract

PURPOSE: Tumor antigen (TA) -targeted monoclonal antibodies (mAb), rituximab, trastuzumab, and cetuximab, are clinically effective for some advanced malignancies, especially in conjunction with chemotherapy and/or radiotherapy. However, these results are only seen in a subset (20% to 30%) of patients. We discuss the immunologic mechanism(s) underlying these clinical findings and their potential role in the variability in patients' clinical response. METHODS: We reviewed the evidence indicating that the effects of TA-targeted mAb-based immunotherapy are mediated not only by inhibition of signaling pathways, but also by cell-mediated cytotoxicity triggered by the infused TA-targeted mAb. We analyzed the immunologic variables that can influence the outcome of antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro and in animal model systems. We also analyzed the correlation reported between these variables and the clinical response to mAb-based immunotherapy. RESULTS: Of the variables that influence ADCC mediated by TA-targeted mAb, only polymorphisms of Fcγ receptors (FcγR) expressed by patients' lymphocytes were correlated with clinical efficacy. However, this correlation is not absolute and is not observed in all malignancies. Thus other variables may be responsible for the antitumor effects seen in mAb-treated patients. We discuss the evidence that triggering of TA-specific cellular immunity by TA-targeted mAb, in conjunction with immune escape mechanisms used by tumor cells, may contribute to the differential clinical responses to mAb-based immunotherapy. CONCLUSION: Identification of the mechanism(s) underlying the clinical response of patients with cancer treated with TA-targeted mAb is crucial to optimizing their application in the clinic and to selecting the patients most likely to benefit from their use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.27.6360

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
IgG Fc Receptors
Ravetch, J. V., & Bolland, S. M. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,686
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,324
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,319
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,272
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,112
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ neu –Positive Metastatic Breast Cancer
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 888
Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study
Burtness, B. A., Goldwasser, M. A., Flood, W. A., Mattar, B. I., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 883
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
Knutson, K. L., & Disis, M. L. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0653-2 · Cited by 697
Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas
Chung, C. H., Ely, K., McGavran, L., Varella‐Garcia, M., Parker, J. S., Parker, N. B., Jarrett, C., Carter, J., Murphy, B. A., Netterville, J. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2587 · Cited by 570
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab
Zhang, W., Gordon, M. A., Schultheis, A. M., Yang, D., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 487
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells
Kalergis, A. M., & Ravetch, J. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020338 · Cited by 373
Dendritic Cells Mediate NK Cell Help for Th1 and CTL Responses: Two-Signal Requirement for the Induction of NK Cell Helper Function
Mailliard, R. B., Son, Y., Redlinger, R. E., Coates, P. T. H., Giermasz, A. S., Morel, P. A., Storkus, W. J., & Kaliński, P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.5.2366 · Cited by 353
Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells
Dhodapkar, K. M., Krasovsky, J., Williamson, B., & Dhodapkar, M. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011097 · Cited by 348
Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma
Fu, K., Weisenburger, D. D., Choi, W. W. L., Perry, K., Smith, L. M., Shi, X., Hans, C. P., Greiner, T. C., Bierman, P. J., Bociek, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9277 · Cited by 334
Complement activation plays a key role in the side‐effects of rituximab treatment
van der Kolk, L. E., Grillo-López, A. J., Baars, J. W., Hack, C. E., & van Oers, M. H. J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03166.x · Cited by 327
Monoclonal antibodies for cancer immunotherapy
Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 312
Self-citation
The Mannose Receptor Mediates Uptake of Soluble but Not of Cell-Associated Antigen for Cross-Presentation
Burgdorf, S., Lukacs‐Kornek, V., & Kurts, C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6770 · Cited by 304
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Disis, M. L., Wallace, D. R., Gooley, T. A., Dang, Y., Slota, M., Lu, H., Coveler, A. L., Childs, J. S., Higgins, D. M., Fintak, P. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6789 · Cited by 301
IL-18–induced CD83+CCR7+NK helper cells
Mailliard, R. B., Alber, S. M., Shen, H., Watkins, S. C., Kirkwood, J. M., Herberman, R. B., & Kaliński, P. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050128 · Cited by 285
Immune complex–mediated antigen presentation induces tumor immunity
Rafiq, K., Bergtold, A., & Clynes, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15640 · Cited by 266
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Pawluczkowycz, A. W., Beurskens, F. J. M., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I., & Taylor, R. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900632 · Cited by 262
Anti-CD20 monoclonal antibodies: historical and future perspectives
Lim, S. H., Beers, S. A., French, R. R., Johnson, P., Glennie, M. J., & Cragg, M. S. (2009) · Haematologica · doi:10.3324/haematol.2008.001628 · Cited by 246
Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2
Varchetta, S., Gibelli, N., Oliviero, B., Nardini, E., Gennari, R., Gatti, G. M., Silva, L. S., Villani, L., Tagliabue, E., Ménard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2068 · Cited by 242
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Emens, L. A., Asquith, J. M., Leatherman, J. M., Kobrin, B. J., Petrik, S., Laiko, M., Levi, J. A., Daphtary, M. M., Biedrzycki, B. A., Wolff, A. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3494 · Cited by 235
Self-citation
HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer
Knowles, L. M., Stabile, L. P., Egloff, A. M., Rothstein, M. E., Thomas, S. M., Gubish, C. T., Lerner, E. C., Seethala, R. R., Suzuki, S., Quesnelle, K. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3252 · Cited by 232
Self-citation
Immune complex–mediated antigen presentation induces tumor immunity
Rafiq, K., Bergtold, A., & Clynes, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215640 · Cited by 232
Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer
Ferris, R. L., Whiteside, T. L., & Ferrone, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2750 · Cited by 224
Self-citation
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
Schneider‐Merck, T., van Bueren, J. J. L., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T. D., Lohse, S., Bleeker, W. K., Peipp, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900847 · Cited by 223
MECT1-MAML2 Fusion Transcript Defines a Favorable Subset of Mucoepidermoid Carcinoma
Okabe, M., Miyabe, S., Nagatsuka, H., Terada, A., Hanai, N., Yokoi, M., Shimozato, K., Eimoto, T., Nakamura, S., Nagai, N., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2376 · Cited by 221
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Taylor, C., Hershman, D. L., Shah, N. D., Suciu‐Foca, N., Petrylak, D. P., Taub, R. N., Vahdat, L. T., Cheng, B., Pegram, M. D., Knutson, K. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0507 · Cited by 215
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
Harari, P. M., Allen, G. W., & Bonner, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8984 · Cited by 214
‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’
Bonavida, B. (2007) · Oncogene · doi:10.1038/sj.onc.1210365 · Cited by 210
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
Abès, R., Gélizé, E., Fridman, W. H., & Teillaud, J. (2010) · Blood · doi:10.1182/blood-2009-10-248609 · Cited by 205
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species
Bellosillo, B., Villamor, N., López‐Guillermo, A., Marcé, S., Esteve, J., Campo, E., Colomer, D., & Montserrat, E. (2001) · Blood · doi:10.1182/blood.v98.9.2771 · Cited by 205
Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype
Weng, W., Czerwinski, D. K., Timmerman, J. M., Hsu, F. J., & Levy, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.003 · Cited by 194
Signaling Through NK Cell-Associated CD137 Promotes Both Helper Function for CD8+ Cytolytic T Cells and Responsiveness to IL-2 But Not Cytolytic Activity
Wilcox, R. A., Tamada, K., Strome, S. E., & Chen, L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4230 · Cited by 181
Natural Killer Cells Produce T Cell–Recruiting Chemokines in Response to Antibody-Coated Tumor Cells
Roda, J. M., Parihar, R., MAGRO, C. M. J., Nuovo, G. J., Tridandapani, S., & Carson, W. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2429 · Cited by 174
Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Bourhis, J., Rivera, F., Mesı́a, R., Awada, A. H., Geoffrois, L., Borel, C., Humblet, Y., Pousa, A. L., Hitt, R., Villegas, M. E. V., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3547 · Cited by 174
Molecular predictors of response to trastuzumab and lapatinib in breast cancer
Esteva, F. J., Yu, D., Hung, M., & Hortobágyi, G. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.216 · Cited by 170
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
Dechant, M., Weisner, W., Berger, S., Peipp, M., Beyer, T. D., Schneider‐Merck, T., van Bueren, J. J. L., Bleeker, W. K., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6226 · Cited by 165
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
Karamouzis, M. V., Grandis, J. R., & Argiris, A. E. (2007) · JAMA · doi:10.1001/jama.298.1.70 · Cited by 163
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
López‐Albaitero, A., Lee, S. C., Morgan, S., Grandis, J. R., Gooding, W. E., Ferrone, S., & Ferris, R. L. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0697-4 · Cited by 160
Self-citation
Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma
Desbois‐Mouthon, C., Baron, A., Eggelpoël, M.-J. B.-V., Fartoux, L., Venot, C., Bladt, F., Housset, C., & Rosmorduc, O. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2980 · Cited by 157
Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL
López‐Albaitero, A., Nayak, J. V., Ogino, T., Machandia, A., Gooding, W. E., DeLeo, A. B., Ferrone, S., & Ferris, R. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3402 · Cited by 156
Self-citation
Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells
Cantoni, C., Bottino, C., Augugliaro, R., Morelli, L., Marcenaro, E., Castriconi, R., Vitale, M., Pende, D., Sivori, S., Millo, R., et al. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199910)29:10 · Cited by 153
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly, R. T., Machiels, J.-P., Emens, L. A., Ercolini, A. M., Okoye, F. I., Lei, R. Y., Weintraub, D., & Jaffee, E. M. (2001) · PubMed · Cited by 151
Self-citation
Cross-talk between G Protein–Coupled Receptor and Epidermal Growth Factor Receptor Signaling Pathways Contributes to Growth and Invasion of Head and Neck Squamous Cell Carcinoma
Thomas, S. M., Bhola, N. E., Zhang, Q. H., Contrucci, S., Wentzel, A. L., Freilino, M. L., Gooding, W. E., Siegfried, J. M., Chan, D. C. F., & Grandis, J. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2876 · Cited by 151
The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor–Positive Tumor Cells is Enhanced By Cytokines
Roda, J. M., Joshi, T., Butchar, J. P., McAlees, J. W., Lehman, A., Tridandapani, S., & Carson, W. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0865 · Cited by 148
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 142
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck
Sharafinski, M. E., Ferris, R. L., Ferrone, S., & Grandis, J. R. (2010) · Head & Neck · doi:10.1002/hed.21365 · Cited by 127
Self-citation
Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis
Beum, P. V., Lindorfer, M. A., Beurskens, F. J. M., Stukenberg, P. T., Lokhorst, H. M., Pawluczkowycz, A. W., Parren, P. W. H. I., van de Winkel, J. G. J., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.822 · Cited by 126
Fc receptor signaling and trafficking: a connection for antigen processing
Amigorena, S., & Bonnerot, C. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01372.x · Cited by 122
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas
Curcio, C., Carlo, E. D., Clynes, R., Smyth, M. J., Boggio, K., Quaglino, E., Spadaro, M., Colombo, M. P., Amici, A. R. D., Lollini, P., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317426 · Cited by 122
Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies
Lin, W., Voskens, C., Zhang, X., Schindler, D. G., Wood, A., Burch, E. E., Wei, Y., Chen, L., Tian, G., Tamada, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122465 · Cited by 118
Natural killer–dendritic cell cross-talk in cancer immunotherapy
Kaliński, P., Mailliard, R. B., Giermasz, A. S., Zeh, H. J., Basse, P. H., Bartlett, D. L., Kirkwood, J. M., Lotze, M. T., & Herberman, R. B. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.10.1303 · Cited by 117
Human Leukocyte Antigen (HLA) Class I Defects in Head and Neck Cancer: Molecular Mechanisms and Clinical Significance
Ferris, R. L., Hunt, J. L., & Ferrone, S. (2005) · Immunologic Research · doi:10.1385/ir:33:2:113 · Cited by 115
Self-citation
Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance
Harbers, S. O., Crocker, A., Catalano, G., D’Agati, V. D., Jung, S., Desai, D. D., & Clynes, R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29470 · Cited by 105
HLA-G expression in human ovarian carcinoma counteracts NK cell function
Lin, A., Yan, W., Xu, H., Gan, M. F., Cai, J., Zhu, M., & Zhou, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm356 · Cited by 101
Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes
Beum, P. V., Mack, D. A., Pawluczkowycz, A. W., Lindorfer, M. A., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.8120 · Cited by 97
Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma
Weng, W., Negrin, R. S., Lavori, P. W., & Horning, S. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0274 · Cited by 93
Phagocytosis requires repeated triggering of macrophage phagocytic receptors during particle ingestion
Shaw, D. R., & Griffin, F. M. (1981) · Nature · doi:10.1038/289409a0 · Cited by 92
Immune Activation by Epidermal Growth Factor Receptor–Specific Monoclonal Antibody Therapy for Head and Neck Cancer
López‐Albaitero, A., & Ferris, R. L. (2007) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.133.12.1277 · Cited by 92
Self-citation
Ten years of rituximab in NHL
Winter, M. C., & Hancock, B. W. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902750114 · Cited by 91
Antigen-Processing Machinery in Human Dendritic Cells: Up-Regulation by Maturation and Down-Regulation by Tumor Cells
Whiteside, T. L., Stanson, J., Shurin, M. R., & Ferrone, S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.1526 · Cited by 90
Self-citation
A Comparison of thein Vitroandin VivoActivities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies
Spiridon, C., Guinn, S. E., & Vitetta, E. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0549 · Cited by 88
Optimal timing for adjuvant radiation therapy in breast cancer
Tsoutsou, P. P., Koukourakis, M. I., Azria, D., & Belkacémi, Y. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.09.002 · Cited by 87
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer
Zhang, Q. H., Bhola, N. E., Lui, V. W. Y., Siwak, D. R., Thomas, S. M., Gubish, C. T., Siegfried, J. M., Mills, G. B., Shin, D. M., & Grandis, J. R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0678 · Cited by 86
The upgraded role of HER3 and HER4 receptors in breast cancer
Koutras, A. K., Fountzilas, G., Kalogeras, K. T., Starakis, I., Iconomou, G., & Kalofonos, H. P. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.04.011 · Cited by 86
Regulatory T cells and tumor immunity
Chattopadhyay, S., Chakraborty, N. G., & Mukherji, B. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0699-9 · Cited by 83
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
Kaumaya, P. T. P., Foy, K. C., Garrett, J. T., Rawale, S. V., Vicari, D., Thurmond, J. M., Lamb, T., Mani, A., Kane, Y., Balint, C. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3883 · Cited by 83
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Mariani, G., Fasolo, A., Benedictis, E. D., & Gianni, L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1298 · Cited by 80
Radiation Combined With EGFR Signal Inhibitors: Head and Neck Cancer Focus
Harari, P. M., & Huang, S.-F. K. (2005) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2005.08.005 · Cited by 80
Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs
Kim, P. S., Armstrong, T. D., Hong, S., Wolpoe, M. E., Weiss, V. L., Manning, E. A., Huang, L., Murata, S., Sgouros, G., Emens, L. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34333 · Cited by 78
Self-citation
HLA‐G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma
Diepstra, A., Poppema, S., Boot, M., Visser, L., Nolte, I. M., Niens, M., Meerman, G. J. T., & van den Berg, A. (2008) · Tissue Antigens · doi:10.1111/j.1399-0039.2008.01005.x · Cited by 77
Effector CD8+CD45RO−CD27−T cells have signalling defects in patients with squamous cell carcinoma of the head and neck
Kuss, I., Donnenberg, A. D., Gooding, W. E., & Whiteside, T. L. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600694 · Cited by 73
Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells
Chen (2009) · Oncology Reports · doi:10.3892/or_00000368 · Cited by 69
The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells
Kowalczyk, A., Gil, M., Horwacik, I., Odrowaz, Z., Kozbor, D., & Rokita, H. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.040 · Cited by 66
Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells
Levy, E. M., Sycz, G., Arriaga, J. M., Barrio, M. M., von Euw, E. M., Morales, S. B., Gonzalez, M. S., Mordoh, J., & Bianchini, M. (2009) · Innate Immunity · doi:10.1177/1753425908101404 · Cited by 66
Current perspective – Trastuzumab
Hall, P. S., & Cameron, D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.013 · Cited by 58
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib
Liu, X., Carlisle, D. L., Swick, M. C., Gaither‐Davis, A., Grandis, J. R., & Siegfried, J. M. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.01.016 · Cited by 56
Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer
Kim, S., Grandis, J. R., Rinaldo, A., Takes, R. P., & Ferlito, A. (2008) · Head & Neck · doi:10.1002/hed.20859 · Cited by 56
Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
Mineo, J. ‐., Bordron, A., Quintin‐Roué, I., Loisel, S., Ster, K. L., Buhé, V., Lagarde, N., & Berthou, C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602089 · Cited by 55
Antitumor Antibodies in the Treatment of Cancer: Fc Receptors Link Opsonic Antibody with Cellular Immunity
Clynes, R. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.02.010 · Cited by 53
Interaction of a human FcγRIIb1 (CD32) isoform with murine and human IgG subclasses
Warmerdam, P. A. M., van den Herik–Oudijk, I. E., Parren, P. W. H. I., WESTERDAAL, N. A. C., & Capel, P. J. (1993) · International Immunology · doi:10.1093/intimm/5.3.239 · Cited by 52
Maturation Pathways of Dendritic Cells Determine TAP1 and TAP2 Levels and Cross-presenting Function
López‐Albaitero, A., Mailliard, R. B., Hackman, T., Filho, P. A. A., Wang, X., Gooding, W. E., Ferrone, S., Kaliński, P., & Ferris, R. L. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a1c24e · Cited by 49
Self-citation
Cetuximab-Related Tumor Lysis Syndrome in Metastatic Colon Carcinoma
Krishnan, G., D’Silva, K. J., & Al-Janadi, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7603 · Cited by 45
Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer.
Whiteside, T. L., Chikamatsu, K., Nagashima, S., & Okada, K. (1996) · PubMed · Cited by 43
A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF–Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence with Immunomodulatory Doses of Cyclophosphamide and Doxorubicin. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Emens, L. A., Armstrong, D. K., Biedrzycki, B. A., Davidson, N. E., Davis-Sproul, J. M., Fetting, J. H., Jaffee, E. M., Onners, B., Piantadosi, S., Reilly, R. T., et al. (2004) · Human Gene Therapy · doi:10.1089/104303404322886165 · Cited by 37
Self-citation
ROLE OF POLYMORPHIC Fc RECEPTOR Fc??RIIa IN CYTOKINE RELEASE AND ADVERSE EFFECTS OF MURINE IgG1 ANTI-CD3/T CELL RECEPTOR ANTIBODY (WT31)1
Tax, W. J. M., Tamboer, W. P. M., Jacobs, C. W. M., Frenken, L. A. M., & Koene, R. A. P. (1997) · Transplantation · doi:10.1097/00007890-199701150-00020 · Cited by 32
Expression of the ULBP ligands for NKG2D by B‐NHL cells plays an important role in determining their susceptibility to rituximab‐induced ADCC
Inagaki, A., Ishida, T., Yano, H., Ishii, T., Kusumoto, S., Ito, A., Ri, M., Mori, F., Ding, J., Komatsu, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24351 · Cited by 31
Enhanced T-Cell Responses to Glioma Cells Coated With the Anti-EGF Receptor Antibody and Targeted to Activating FcγRs on Human Dendritic Cells
Banerjee, D., Matthews, P., Matayeva, E., Kaufman, J. L., Steinman, R. M., & Dhodapkar, K. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815a5892 · Cited by 31
Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab
Rodríguez, J., Viúdez, A., Ponz‐Sarvisé, M., Gil-Aldea, I., Chopitea, A., García‐Foncillas, J., & Bazo, I. G. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.07.005 · Cited by 31
Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients
Filho, P. A. A., López‐Albaitero, A., Gooding, W. E., & Ferris, R. L. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b8f421 · Cited by 30
Self-citation
Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer
Lango, M. N., Shin, D. M., & Grandis, J. R. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200105000-00007 · Cited by 29
EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab?
Valentini, A. M., Pirrelli, M., & Caruso, M. L. (2008) · PubMed · Cited by 27
HLA-G in Melanoma: A New Strategy to Escape from Immunosurveillance?
Ugurel, S., Reinhold, U., & Tilgen, W. (2002) · Oncology Research and Treatment · doi:10.1159/000055222 · Cited by 26
Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li, D., Ronson, B. B., Guo, M., Liu, S., Bishop, J. S., Echo, D. A. V., & O'Malley, B. W. (2002) · PubMed · Cited by 24
Association of FcγRIIa and FcγRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan
Bibeau, F., Crapez, E., Fiore, F. D., Thézenas, S., Sabourin, J., Lamy, A., Frébourg, T., Michel, P., Ychou, M., & Boissière‐Michot, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11004 · Cited by 23
Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME)
Vermorken, J. B., Mesı́a, R., Vega-Villegas, M. E., Remenár, É., Hitt, R., Kawecki, A., Rottey, S., Zabolotnyy, D., Erfan, J., & Amellal, N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.5537 · Cited by 21
Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies
Lee, S. C., López‐Albaitero, A., & Ferris, R. L. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0023-5 · Cited by 21
Self-citation
Pathologic Complete Response to Preoperative Sequential Doxorubicin/Cyclophosphamide and Single-Agent Taxane With or Without Trastuzumab in Stage II/III HER2-Positive Breast Cancer
Chumsri, S., Jeter, S. C., Jacobs, L. K., Nassar, H., Armstrong, D. K., Emens, L. A., Fetting, J. H., Lange, J. R., Riley, C. D., Tsangaris, T. N., et al. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.005 · Cited by 17
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
Toi, M., Sperinde, J., Huang, W., Saji, S., Winslow, J. W., Jin, X., Tan, Y., Ohno, S., Nakamura, S., Iwata, H., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-56 · Cited by 17
Head and neck cancer immunotherapy: Clinical evaluation
Leibowitz, M. S., Nayak, J. V., & Ferris, R. L. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0025-8 · Cited by 15
Self-citation
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity
Coveler, A. L., Vivian Goodell, A., Webster, D. J., Salazar, L. G., Fintak, P. A., Childs, J. S., Higgins, D. M., & Disis, M. L. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9910-y · Cited by 14
Expansion of natural killer cells in patients with head and neck cancer: Detection of “noninhibitory” (activating) killer Ig‐like receptors on circulating natural killer cells
Melioli, G., Semino, C., Margarino, G., Mereu, P., Scala, M., Cangemi, G., Crocetti, E., Machì, A. M., & Ferlazzo, G. (2002) · Head & Neck · doi:10.1002/hed.10198 · Cited by 14
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck
William, W. N., Kim, E. S., & Herbst, R. S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/ncponc1321 · Cited by 13
Cetuximab for Metastatic Colorectal Cancer
Roila, F., Garassino, M. C., & Ballatori, E. (2009) · New England Journal of Medicine · doi:10.1056/nejmc090927 · Cited by 11
Cetuximab, chemotherapy and KRAS status in mCRC
Gill, S., & Goldberg, R. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.83 · Cited by 8
Cetuximab plus chemotherapy in patients with advanced NSCLC
Rasul, K. I., & Kerr, R. S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.108 · Cited by 5
Untitled work
Bischof, A. (2000) · doi:10.1002/1521-4141(200003)30:3

Flagged first, then by citations

Research works printed but not linked: 9

Abes R, Blood
Reilly RT, 2001, Cancer Res, 61, 880
Sharafanski M, Head and Neck
Valentini AM, 2008, Curr Opin Mol Ther, 10, 124
Zhao WP, 2009, Oncol Rep, 21, 1405
Whiteside TL, 1996, Anticancer Res, 16, 2357
Ugurel S, 2002, Onkologie, 25, 129
Li D, 2002, Cancer Res, 62, 4023
10.1158/1078-0432.CCR-05-2750 · DOI

Sorted by citations

Antibody therapy of cancer
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,244
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,266
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
Monoclonal Antibodies in Cancer Therapy
Zahavi, D. J., & Weiner, L. M. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 905

See all 321

Authors: Ferris, R. L., Jaffee, E. M., & Ferrone, S.
Affiliations: Johns Hopkins University (US)
ORCID: Ferris, Robert L.
Jaffee, Elizabeth M.
Ferrone, Soldano
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2010-10-01
Volume: 28
Issue: 28
Pages: 4390-4399
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.27.6360
PMC: PMC2954137
OpenAlex: W2112887207
Cited by: 320
References: 122
Citations by year: 2026: 6 · 2025: 12 · 2024: 7 · 2023: 28 · 2022: 11 · 2021: 13 · 2020: 17 · 2019: 19 · 2018: 13 · 2017: 30 · 2016: 26 · 2015: 33 · 2014: 18 · 2013: 28 · 2012: 34
FWCI: 3.94
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Bristol-Myers Squibb
American Society of Clinical Oncology
National Cancer Institute (P50CA097190)
National Institute of Dental and Craniofacial Research (R01DE019727)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: antibody-dependent cellular cytotoxicity, Fc gamma receptor polymorphisms, tumor immune evasion, cell-mediated immunity, rituximab, trastuzumab, cetuximab, signaling pathway inhibition
MeSH terms: Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Humans, Immunity, Cellular, Immunotherapy, Neoplasms, Receptors, Fc, Signal Transduction, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks